Answers are grounded in this paper and cite their sources.
Aging is a major risk factor for Alzheimer's disease and related dementias (AD/ADRD). Yet, the physiological relationships linking age-related changes in peripheral biomarkers and measures of brain structure have only recently begun to be explored. Nonhuman primates, whose brains naturally express some of the pathologic hallmarks of AD/ADRD, including amyloid-beta (Aβ) plaques, vascular amyloid, and neurofibrillary tangles, represent a critical translational bridge between rodent models and humans. Here, we utilized ultrasensitive multiplex assays and structural MRI to examine the relationship of plasma AD/ADRD biomarkers with age, sex, and whole brain cortical thickness (CT) and gray matter volume (GMV) in a cohort of chimpanzees (Pan troglodytes), humans' closest extant living relatives. Plasma levels (pg/ml) of total tau, phosphorylated tau 217 (pTau217), Aβ40, Aβ42, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured in a cross-sectional sample of 154 chimpanzees ranging from 12-57 years of age. As in humans, aging was associated with increased plasma total tau, pTau217, Aβ40, Aβ42, GFAP, and NfL levels, as well as reduced whole brain CT and GMV in chimpanzees. The ratio of plasma Aβ42/Aβ40 increased with age in male chimpanzees, whereas aging was not significantly associated with the ratio of pTau217/Aβ42. Mediation analyses revealed that age-related increases in plasma Aβ42 mediated whole brain GMV atrophy in chimpanzees. Together, these findings demonstrate that plasma AD/ADRD biomarkers and measures of brain structure undergo age-related changes in chimpanzees, which is highly relevant to the study of human aging and AD/ADRD.
No takes yet. Share an insight, caveat, or question.
Edler et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: